BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Given New $25.00 Price Target at JPMorgan Chase & Co.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its price target cut by JPMorgan Chase & Co. from $27.00 to $25.00 in a research note released on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. UBS Group cut shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research report on Wednesday, July 8th. Canaccord Genuity Group assumed coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Oppenheimer assumed coverage on BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BridgeBio Oncology Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $24.40.

BridgeBio Oncology Therapeutics Stock Performance

NASDAQ:BBOT opened at $9.06 on Friday. The company has a market cap of $726.34 million, a PE ratio of -3.28 and a beta of 0.36. The stock has a 50-day simple moving average of $8.29 and a 200 day simple moving average of $9.08. BridgeBio Oncology Therapeutics has a 52-week low of $7.00 and a 52-week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($705.20) earnings per share for the quarter. On average, research analysts predict that BridgeBio Oncology Therapeutics will post -2.32 earnings per share for the current fiscal year.

Institutional Trading of BridgeBio Oncology Therapeutics

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in shares of BridgeBio Oncology Therapeutics by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after acquiring an additional 20,385 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $1,185,000. BIT Capital GmbH acquired a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $313,000. CIBC Private Wealth Group LLC acquired a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $63,000. Finally, Renaissance Technologies LLC bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth $930,000. 54.89% of the stock is owned by institutional investors and hedge funds.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.